Korro Bio initiated with an Outperform at BMO Capital

BMO Capital initiated coverage of Korro Bio with an Outperform rating and $120 price target. Korro leverages its novel RNA editing platform to correct pathogenic mutations at the mRNA level or create de novo proteins with desired functionality, the analyst tells investors in a research note. The firm sees the company as a leader in RNA editing and awaits the first clinical data in mid-2025.